2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132210
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane 116673-45-1 98%
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM.
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
  • HY-13221A
    BRL 54443 maleate 1197333-54-2 98%
    BRL 54443 (MALEATE) is a potent 5-HT1E/1F receptor agonist (Ki values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.
    BRL 54443 maleate
  • HY-132583
    IONIS-DNM2-2.5Rx 2857839-05-3
    IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting dynamin 2. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM).
    IONIS-DNM2-2.5Rx
  • HY-13289B
    (R)-Nepicastat hydrochloride 195881-94-8 98%
    (R)-Nepicastat hydrochloride is the isomer of Nepicastat (HY-13289). Nepicastat (SYN117) is a selective，potent，and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB).
    (R)-Nepicastat hydrochloride
  • HY-13295S
    Vinpocetine-d5 2734920-39-7 98%
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine-d5
  • HY-133036
    APJ receptor agonist 1 2287153-38-0 98%
    APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC50s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure.
    APJ receptor agonist 1
  • HY-133214
    Cyclazosin hydrochloride 146929-33-1 98%
    Cyclazosin hydrochloride is an α1B-adrenergic receptor antagonist. Cyclazosin hydrochloride has high specificity for α-adrenergic receptors, with pKi values of 9.23-9.57 and 8.18-8.41 for O/1A (O/la) and OflB (alb) adrenergic receptors, respectively. However, Cyclazosin hydrochloride cannot distinguish between cloned alb and alo adrenergic receptors, which have pKi values of 9.23 and 9.28, respectively.
    Cyclazosin hydrochloride
  • HY-13338A
    (S)-Mabuterol 56707-25-6 98%
    (S)-Mabuterol is a selective β2 adrenoreceptor agonist that demonstrates blood pressure reduction and increased heart rate and contractile force in animal models.
    (S)-Mabuterol
  • HY-13338S
    Mabuterol-d9 1246819-58-8 98%
    Mabuterol-d9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor.
    Mabuterol-d9
  • HY-133567
    SET7-IN-DC21 2567886-53-5 98%
    SET7-IN-DC21 is a selective, potent SET7 inhibitor (IC50 = 15.93 μM; KD = 18.00 μM). SET7-IN-DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. SET7-IN-DC21 can be used for the researches of cancer, infection, inflammation, metabolic and cardiovascular disease, such as breast cancer.
    SET7-IN-DC21
  • HY-133589
    Fulvine 6029-87-4 98%
    Fulvine is a pyrrolizidine alkaloid isolated from the seeds of Crotalaria fulva. Fulvine is hepatotoxic and can be used to induce hypertensive pulmonary vascular disease in vivo.
    Fulvine
  • HY-133715
    Pilsicainide 88069-67-4 98%
    Pilsicainide (SUN 1165 free acid) is a potent sodium channel blocker and potent class Ic antiarrhythmic agent.
    Pilsicainide
  • HY-133727
    Terfenadine N-oxide 634901-83-0 98%
    Terfenadine N-oxide, an N-oxide derivative of Terfenadine (HY-B1193), is a histamine H1 receptor antagonist (IC50 = 2.73 μM) and an hERG potassium channel inhibitor (IC50 = 0.698 μM). Terfenadine N-oxide is can be used for the research of histamine-related allergic diseases and hERG channel-associated arrhythmias.
    Terfenadine N-oxide
  • HY-133806
    Fumarranol 912569-37-0 98%
    Fumarranol, a Fumagillin (HY-B0751) analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration.
    Fumarranol
  • HY-133854
    L 8412 50602-48-7 98%
    L 8412 is a potent anti-adrenergic agent and anti-anginal agent.
    L 8412
  • HY-133924
    18-Deoxyherboxidiene 1200128-66-0 98%
    18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research.
    18-Deoxyherboxidiene
  • HY-133931
    Bimakalim 117545-11-6 98%
    Bimakalim (EMD-52692) is an ATP-sensitive potassium channel opener. Bimakalim reduces transmural MPO activity. Bimakalim mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs.
    Bimakalim
  • HY-133981
    Desmethylene tadalafil 171489-03-5 98%
    Desmethylene tadalafil is a metabolite of Tadalafil (HY-90009A). The formation of Desmethylene tadalafil mediated predominantly by CYP3A4.
    Desmethylene tadalafil
  • HY-134028
    Arucadiol 105037-85-2 98%
    Arucadiol is a rosane-type diterpenoid anti-inflammatory agent. 5 μM Arucadiol significantly inhibits LPS-induced TNF-α, IL-1β, and IL-8 production (inhibition rates of 39.8%, 44.4%, and 34.5%, respectively). Arucadiol exerts its anti-inflammatory activity by inhibiting the mRNA and protein expression of inflammatory cytokines and can be used in research on inflammation-related cardiovascular diseases such as atherosclerosis. Arucadiol can be naturally extracted from the roots of Salvia miltiorrhiza var. alba.
    Arucadiol
  • HY-134221
    S-Nitroso-N-acetylcysteine 56577-02-7 98%
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis.
    S-Nitroso-N-acetylcysteine
Cat. No. Product Name / Synonyms Application Reactivity